CERVOMED INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.9 USD | -2.01% |
|
-0.99% | +213.24% |
| 04-08 | Canaccord Genuity Adjusts Price Target on CervoMed to $65 From $50, Maintains Buy Rating | MT |
| 03-29 | CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 8.4M 11.47M | Sales 2025 * | 6.5M 8.87M | Capitalization | 197M 269M |
|---|---|---|---|---|---|
| Net income 2024 * | -12M -16.38M | Net income 2025 * | -26M -35.49M | EV / Sales 2024 * | 18.1 x |
| Net cash position 2024 * | 45.3M 61.84M | Net cash position 2025 * | 113M 154M | EV / Sales 2025 * | 13 x |
| P/E ratio 2024 * |
-17.4
x | P/E ratio 2025 * |
-10.8
x | Employees | 8 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.06% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.01% | ||
| 1 week | -0.99% | ||
| Current month | -1.61% | ||
| 1 month | +3.28% | ||
| 3 months | +117.47% | ||
| 6 months | +140.68% | ||
| Current year | +213.24% |
1 week
23.62
25.69
1 month
22.0025.92
Current year
7.0226.38
1 year
4.2826.38
3 years
4.2826.38
5 years
4.2826.38
10 years
4.2826.38
| Managers | Title | Age | Since |
|---|---|---|---|
John Alam
CEO | Chief Executive Officer | 62 | 23-08-15 |
William Tanner
DFI | Director of Finance/CFO | 66 | 23-08-15 |
Kelly Blackburn
CTO | Chief Tech/Sci/R&D Officer | 60 | 23-08-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joshua Boger
CHM | Chairman | 72 | 02-06 |
John Alam
CEO | Chief Executive Officer | 62 | 23-08-15 |
Frank Zavrl
BRD | Director/Board Member | 58 | 23-08-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 23.9 | -2.01% | 18,865 |
| 24-05-08 | 24.39 | -0.04% | 33,037 |
| 24-05-07 | 24.4 | +0.29% | 24,377 |
| 24-05-06 | 24.33 | +1.12% | 62,490 |
| 24-05-03 | 24.06 | -0.33% | 38,332 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm
More quotes
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimerâs disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
23.9
USD
Average target price
47.5
USD
Spread / Average Target
+98.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +213.24% | 197M | |
| +2.97% | 108B | |
| +10.21% | 104B | |
| +2.59% | 22.33B | |
| -12.77% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -6.50% | 17.64B | |
| +6.00% | 14.05B | |
| +37.20% | 12.51B |
- Stock Market
- Equities
- CRVO Stock